Research yields first detailed view of morphing Parkinson's protein

by Emil Venere

This graphic illustrates the morphing structure of a brain protein thought to play a role in Parkinson's disease, information that could aid the development of medications to treat the condition. Researchers have taken detailed images and measurements of the changing structure for the first time. Findings reveal that the protein morphs from its globular shape into "protofibril" strands that assemble into pore-like rings. These rings then open up, forming pairs of protofibrils that assemble into fibrils through hydrogen bonds. Credit: Purdue University/ Hangyu Zhang

(Medical Xpress)—Researchers have taken detailed images and measurements of the morphing structure of a brain protein thought to play a role in Parkinson's disease, information that could aid the development of medications to treat the condition.

The protein, called alpha synuclein (pronounced sine-yoo-cline), ordinarily exists in a globular shape. However, the protein morphs into harmful structures known as amyloid fibrils, which are linked to protein molecules that form in the brains of patients with neurodegenerative diseases.

"The abnormal protein formation characterizes a considerable number of human diseases, such as Alzheimer's, Parkinson's and Huntington's diseases and type II diabetes," said Lia Stanciu, an associate professor of materials engineering at Purdue University.

Until now, the transition from globular to fibrils had not been captured and measured.

Researchers incubated the protein in a laboratory and then used an electron microscope and a technique called cryoelectron microscopy to snap thousands of pictures over 24 hours, capturing its changing shape. The protein was frozen at specific time intervals with liquid nitrogen.

Findings reveal that the protein morphs from its globular shape into "protofibril" strands that assemble into pore-like rings. These rings then open up, forming pairs of protofibrils that assemble into fibrils through hydrogen bonds.

"We found a correlation between proto?brils in these rings and the ?brils, for the ?rst time to our knowledge, by measuring their true sizes and visualizing the aggregation steps," Stanciu said. "A better understanding of the mechanism yields fresh insight into the pathogenesis of amyloid-related diseases and may provide us the opportunity to develop additional therapeutic strategies."

Parkinson's disease affects 1 percent to 2 percent of people older than 60, and an increase in its prevalence is anticipated in coming decades.

The findings were detailed in a research paper appearing in the June issue of the Biophysical Journal. The paper was authored by doctoral student Hangyu Zhang; former postdoctoral research associate Amy Griggs; Jean-Christophe Rochet, an associate professor of medicinal chemistry and molecular pharmacology; and Stanciu.

The researchers caused the protein to morph into fibrils by exposing it to copper, mimicking what happens when people are exposed to lead and other heavy metals. The contaminants interfere with the protein, changing the oxidation states of ions in its structure.

Related Stories

Alzheimer's disease is a progressive degenerative brain disease most commonly characterized by memory deficits. Loss of memory function, in particular, is known to be caused by neuronal damage arising from ...

UCLA chemists and molecular biologists have for the first time used a "structure-based" approach to drug design to identify compounds with the potential to delay or treat Alzheimer's disease, and possibly Parkinson's, Lou ...

Neurodegenerative diseases are not all alike. Two individuals suffering from the same disease may experience very different age of onset, symptoms, severity, and constellation of impairments, as well as different ...

Changes in the structure of proteins can lead to various diseases, such as Alzheimer's, type 2 diabetes and corneal dystrophy. A research team from Aarhus University has now discovered how a particular protein ...

Recommended for you

Although levodopa remains the "gold standard" to effectively control motor deficits in the treatment of early stage Parkinson's disease (PD), it loses effectiveness as the disease progresses. After four to six years of treatment ...

Patients with Parkinson's disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast vision, this is often overlooked during routine eye exams. In the current ...

Parkinson's disease is the second neurodegenerative disease in number of patients after Alzheimer's disease. The Technical Research Centre for Dependency Care and Autonomous Living (CETpD) of the Universitat ...

The use of statins may not be associated with lowering risk for Parkinson's disease, according to a new study led by researchers at Penn State College of Medicine and National Institute of Environmental Health ...

Researchers have long sought treatments that can slow the progression of Parkinson's disease. Current treatments have for decades been only symptomatic in nature, supplying the neurotransmitter dopamine, which the dying nerve ...

User comments

Please sign in to add a comment.
Registration is free, and takes less than a minute.
Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.